Small molecules such as NEMO-binding domain (NBD) peptide and NEDD-8 activating enzyme inhibitor (Pevonedistat) inhibited nuclear factor kappa-B (NF-kB) activity, commonly upregulated in B-cell lymphoma, and induced apoptosis of malignant B lymphocytes 11, 12. The generation of this chimeric antibody against CD20 showed good binding affinity to canine B cells and induced antibody-dependent cell-mediated cytotoxicity (ADCC) against canine neoplastic B cells in vitro and in vivo studies 8– 10. Anti-canine CD20 monoclonal antibody has also been developed for treating B-cell lymphomas. Vaccinated dogs compared to placebo group showed promising results which prolonged time to progression and lymphoma-specific survival with no local or systemic adverse effects 6, 7. An autologous heat shock protein peptide chaperone (HSPPC) vaccine was evaluated the efficacy of antitumor effect in dogs with B-cell lymphoma treated with CHOP-based protocol. Therefore, novel strategies such as immunotherapy and target drugs have been investigated to enhance the effectiveness of therapy in canine lymphomas 5. The CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) protocol is the standard-of-care in dogs with naïve intermediate- and high-grade lymphoma 4 however, refractory and relapsed diseases present major barriers to successful treatment. In contrast, high-grade lymphomas such as DLBCL and PTCL are related to poorer prognoses and a shorter survival time 3. Both MZL and TZL are low-grade and have indolent behaviors that cause a low mortality rate 2. Peripheral T-cell lymphoma (PTCL) and T-zone lymphoma (TZL) are frequently reported as T subtypes 1. Based on cellular morphology, cell lineage and topography, the most common subtypes of B-cell lymphoma in dogs are diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL) 1. Multicentric lymphoma is the most relevant anatomical form in dogs. Therefore, this SNP’s lymphoma panel provides valuable information that we can use to outline a prognosis and develop a treatment plan for the targeted therapy of each dog. Dogs treated with COP chemotherapy and contained 3–5 variants at SEL1L were associated with decreased median OST. Also, DLBCL dogs (CHOP-based treatment) with c-Kit T425= had a poorer prognosis with shorter median overall survival times (OST) than dogs with the wild type. The lesser mutual SNPs were observed at SEL1L, excluding a cocker spaniel, and c-Kit, with the exception of a pug and a French bulldog. All dogs presented single nucleotide polymorphisms (SNPs) at HYAL4 and SATB1 genes. Lymph node biopsy was performed from 60 dogs with B-cell lymphoma comprising 47 purebred and 13 crossbred dogs. These variants were chosen based on the high prevalence observed in canine B- and T-cell lymphomas, their significance for target therapy, and compatibility for multiplex PCR amplification. This study aimed to assemble 41 variants of the previously reported genes and to investigate these variants in canine DLBCL using the Agena MassARRAY platform. The module is an add-on to the MassARRAY Analyzer.Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma in dogs with a multicentric form. The Chip prep module can process eight 96-pad SpectroCHIP Arrays in less than a day and it includes on-board cooling and storage, which allow overnight processing and storage of two additional SpectroCHIP Arrays. “The addition of the Chip prep module simplifies our process and reduces the potential for contamination,” added Tammy Ray, Medical Technologist for the laboratory. Bobbie Sutton, Pathologist and Director of Molecular Pathology.
“The flexibility to refine complicated testing methods quickly and easily has made the MassARRAY System an integral part of our molecular testing,” said Dr. South Bend Medical Foundation, an early access site, has realized many of the benefits of the MassARRAY System in their clinical laboratory. High throughput laboratories can capitalize on the quick load-and-go process of the Chip prep module. It automates several processing steps, including dispensing and desalting samples onto the SpectroCHIP® Array, and subsequently loading these onto the MassARRAY Analyzer.
Massarray agena manual#
The Chip prep module is designed to minimize hands-on time and reduce the risk of cross contamination associated with manual sample handling.
0 kommentar(er)
